Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.43 |
| ▸ | GAA | P10253 | 2/20 | 0.43 |
| ▸ | GLA | P06280 | 1/20 | 0.43 |
| ▸ | MTOR | P42345 | 1/20 | 0.41 |
| ▸ | ADK | P55263 | 1/20 | 0.41 |
| ▸ | NISCH | Q9Y2I1 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.40 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.38 |
| ▸ | RAB9A | P51151 | 7/20 | 0.37 |
| ▸ | MEN1 | O00255 | 4/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.37 |
| ▸ | MAPT | P10636 | 4/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | BLM | P54132 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 6/20 | 0.36 |
| ▸ | CA1 | P00915 | 2/20 | 0.36 |
| ▸ | CA2 | P00918 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1845553 | 1.00 | KDM4E (0.43) | KDM4EGAAGLAMTORADK | |
| Benzene SCHEMBL28173940 | 0.73 | MEN1 (0.48) | MTORADKNISCHTAAR1RAB9A | |
| SCHEMBL3069084 | 0.71 | KMT2A (0.57) | KDM4EGAAMTORADKNISCH | |
| SCHEMBL1922167 | 0.71 | MTOR (0.45) | KDM4EGAAGLAMTORADK | |
| SCHEMBL3069082 | 0.71 | KMT2A (0.57) | KDM4EGAAMTORADKNISCH | |
| SCHEMBL27821030 | 0.70 | LMNA (0.48) | KDM4EGAAGLALMNAL3MBTL1 | |
| SCHEMBL14062519 | 0.70 | — | — | |
| SCHEMBL5500536 | 0.70 | — | — | |
| SCHEMBL11107953 | 0.67 | MEN1 (0.52) | KDM4EMTORADKNISCHTAAR1 | |
| SCHEMBL11103862 | 0.67 | MEN1 (0.52) | KDM4EMTORADKNISCHTAAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023096850-A1 | PHOSPHOINOSITIDE 3 KINASE GAMMA INHIBITORS AND COMPOSITIONS AND METHODS THEREOF | GEODE THERAPEUTICS INC. (US) | 2023-06-01 | — | — | WO | disclosed |
| EP-3044221-A1 | 3-ARYL-5-SUBSTITUTED-ISOQUINOLIN-1-ONE COMPOUNDS AND THEIR THERAPEUTIC USE | Institute of Cancer Research: Royal Cancer Hospital (The) (GB) | 2016-07-20 | — | — | EP | disclosed |
| WO-2015036759-A1 | 3-ARYL-5-SUBSTITUTED-ISOQUINOLIN-1-ONE COMPOUNDS AND THEIR THERAPEUTIC USE | INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (THE) (GB) | 2015-03-19 | — | — | WO | disclosed |
| US-7041672-B2 | Substituted aryl 1, 4-pyrazine derivatives | PFIZER INC. (US) | 2006-05-09 | — | — | US | disclosed |
| US-6992087-B2 | Substituted aryl 1,4-pyrazine derivatives | PFIZER INC (US) | 2006-01-31 | — | — | US | disclosed |
| US-20050049257-A1 | Substituted aryl 1, 4-pyrazine derivatives | PFIZER INC | 2005-03-03 | — | — | US | disclosed |
| EP-1446387-A1 | SUBSTITUTED ARYL 1,4-PYRAZINE DERIVATIVES | PHARMACIA & UPJOHN COMPANY (US) | 2004-08-18 | — | — | EP | disclosed |
| US-20030144297-A1 | Substituted aryl 1,4-pyrazine derivatives | PHARMACIA & UPJOHN COMPANY | 2003-07-31 | — | — | US | disclosed |
| WO-2003045924-A1 | SUBSTITUTED ARYL 1,4-PYRAZINE DERIVATIVES | PHARMACIA & UPJOHN COMPANY (US) | 2003-06-05 | — | — | WO | disclosed |
| US-5552427-A | ANTITUMOR AGENTS AND ANTICARCINOGENIC AGENTS | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1996-09-03 | — | — | US | disclosed |
| EP-0656210-A1 | Imidazole derivatives as glutaminose inhibitors | Takeda Chemical Industries, Ltd. (JP) | 1995-06-07 | — | — | EP | disclosed |
| CN-1016169-B | PROCESS FOR PREPARING IMIDAZOLE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 1992-04-08 | — | — | CN | disclosed |
| CN-88101452-A | Imdazole derivatives | — | 1988-10-05 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050049257-A1 | Substituted aryl 1, 4-pyrazine derivatives | HTR2C, HTR4, HTR5A | KDM4E 1364/4885GAA 3613/4885GLA 3248/4885 |
| US-20030144297-A1 | Substituted aryl 1,4-pyrazine derivatives | HTR2C, HTR4, HTR5A | KDM4E 1364/4885GAA 3613/4885GLA 3248/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.